Literature DB >> 16153397

Transporters and drug therapy: implications for drug disposition and disease.

Richard H Ho1, Richard B Kim.   

Abstract

The efficacy of drug therapy results from the complex interplay of multiple processes that govern drug disposition and response. Most studies to date have focused on the contribution of drug-metabolizing enzymes to the drug disposition process. However, over the past decade, it has become increasingly apparent that carrier-mediated processes, or transporters, also play critical roles in the overall disposition of numerous drugs in clinical use. In addition to their roles in xenobiotic transport, drug transporters often mediate important physiologic functions via transport of endogenous substrates such as amino acids, bile acids, and hormones that are critical for maintenance of normal homeostasis. In this review we focus on the emerging field of transporter proteins in relation to the drug disposition process, with particular emphasis on clinical implications of transporters to drug-drug interactions and subsequent development of adverse effects, interindividual variability in drug response, and human disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16153397     DOI: 10.1016/j.clpt.2005.05.011

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  102 in total

Review 1.  Azole interactions with multidrug therapy in pediatric oncology.

Authors:  Antonio Ruggiero; Roberta Arena; Andrea Battista; Daniela Rizzo; Giorgio Attinà; Riccardo Riccardi
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

2.  Pharmacogenetics: implementing personalized medicine.

Authors:  Enrico Mini; Stefania Nobili
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

3.  Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Jun Kato; Akiko Yamane; Masatoshi Sakurai; Sumiko Kohashi; Taku Kikuchi; Yukako Ono; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2012-03-30       Impact factor: 2.490

4.  Docetaxel Induced Sclerosing Cholangitis.

Authors:  Jennifer L Horsley-Silva; Elizabeth N Dow; Christine O Menias; Maxwell L Smith; Estrella M Carballido; Keith D Lindor; Hugo E Vargas
Journal:  Dig Dis Sci       Date:  2015-12       Impact factor: 3.199

Review 5.  Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

Authors:  Minlu Hu; Sravan Kumar Patel; Tian Zhou; Lisa C Rohan
Journal:  J Control Release       Date:  2015-08-13       Impact factor: 9.776

6.  Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).

Authors:  Manthena V Varma; Stefanus J Steyn; Charlotte Allerton; Ayman F El-Kattan
Journal:  Pharm Res       Date:  2015-07-09       Impact factor: 4.200

7.  The role of permeability in drug ADME/PK, interactions and toxicity--presentation of a permeability-based classification system (PCS) for prediction of ADME/PK in humans.

Authors:  Urban Fagerholm
Journal:  Pharm Res       Date:  2007-08-21       Impact factor: 4.200

Review 8.  Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics.

Authors:  Andrea R Thurman; Sharon Anderson; Gustavo F Doncel
Journal:  Am J Reprod Immunol       Date:  2014-02-13       Impact factor: 3.886

Review 9.  Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Authors:  Caroline Bazzoli; Vincent Jullien; Clotilde Le Tiec; Elisabeth Rey; France Mentré; Anne-Marie Taburet
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

Review 10.  Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.

Authors:  Pertti J Neuvonen; Janne T Backman; Mikko Niemi
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.